Dr Dave Simpson

 

Dave Simpson PhD is co-founder and CEO of Glythera Limited, an Antibody Drug Conjugate development company underpinned by its proprietary conjugation platforms. Having raised c£10.0m to date through institutional investors and Innovate UK funding, Glythera is rapidly progressing its ADC portfolio towards the clinic.Dr Dave Simpson has over 18 years of pharmaceutical industry experience including biotech, contract manufacturing organisations and major Pharma and has extensive experience in process/ product development and commercialisation strategies for multiple product classes including leading the development of Allergan’s biosimilar programmes.Through his commercial and technical background, Dr Dave Simpson continues to support a number of UK Universities, biotech companies, US corporations and investors in developing their technical, product and commercialization strategies.